RT Journal Article
SR Electronic
T1 Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20228197
DO 10.1101/2020.11.09.20228197
A1 Alessandra Bettiol
A1 Renato Alberto Sinico
A1 Franco Schiavon
A1 Sara Monti
A1 Enrica Paola Bozzolo
A1 Franco Franceschini
A1 Marcello Govoni
A1 Claudio Lunardi
A1 Giuseppe Guida
A1 Giuseppe Lopalco
A1 Giuseppe Paolazzi
A1 Angelo Vacca
A1 Gina Gregorini
A1 Pietro Leccese
A1 Matteo Piga
A1 Fabrizio Conti
A1 Paolo Fraticelli
A1 Luca Quartuccio
A1 Federico Alberici
A1 Carlo Salvarani
A1 Silvano Bettio
A1 Simone Negrini
A1 Carlo Selmi
A1 Savino Sciascia
A1 Gabriella Moroni
A1 Loredana Colla
A1 Carlo Manno
A1 Maria Letizia Urban
A1 Alfredo Vannacci
A1 Maria Rosa Pozzi
A1 Paolo Fabbrini
A1 Stefano Polti
A1 Mara Felicetti
A1 Maria Rita Marchi
A1 Roberto Padoan
A1 Paolo Delvino
A1 Roberto Caporali
A1 Carlomaurizio Montecucco
A1 Lorenzo Dagna
A1 Adriana Cariddi
A1 Paola Toniati
A1 Silvia Tamanini
A1 Federica Furini
A1 Alessandra Bortoluzzi
A1 Elisa Tinazzi
A1 Lorenzo Delfino
A1 Iuliana Badiu
A1 Giovanni Rolla
A1 Vincenzo Venerito
A1 Florenzo Iannone
A1 Alvise Berti
A1 Roberto Bortolotti
A1 Vito Racanelli
A1 Guido Jeannin
A1 Angela Padula
A1 Alberto Cauli
A1 Roberta Priori
A1 Armando Gabrielli
A1 Milena Bond
A1 Martina Tedesco
A1 Giulia Pazzola
A1 Paola Tomietto
A1 Marco Pellecchio
A1 Chiara Marvisi
A1 Federica Maritati
A1 Alessandra Palmisano
A1 Christian Dejaco
A1 Johann Willeit
A1 Stefan Kiechl
A1 Iacopo Olivotto
A1 Peter Willeit
A1 Domenico Prisco
A1 Augusto Vaglio
A1 Giacomo Emmi
A1 on behalf of the Italian EGPA Consortium
YR 2021
UL http://medrxiv.org/content/early/2021/01/06/2020.11.09.20228197.abstract
AB Background and objective Systemic small vessel vasculitides carry an increased risk of acute arterial and venous thromboembolic events (AVTE); however, this risk has not been systematically explored in Eosinophilic Granulomatosis with Polyangiitis (EGPA). This study assessed the occurrence and main risk factors of AVTE among EGPA patients as compared to the general community from the population-based Bruneck cohort.Methods We conducted a retrospective multicenter cohort study on 573 EGPA patients. Clinical and serological data were collected at diagnosis. Occurrence of AVTE and time to the first AVTE after EGPA diagnosis were recorded. Age-standardized event rate (SER) of AVTE as compared to the reference cohort was assessed. Cox regression was applied to identify AVTE predictors.Results 129 EGPA patients (22.5%) had AVTE, considered as potentially life-threatening in 55.8%. Seventy patients experienced an AVTE prior to diagnosis (of whom 58.6% in the two years before diagnosis) and 75 following EGPA diagnosis, of whom 56% in the two subsequent years. The SER of AVTE as compared to the reference cohort was 2.10 (95% CI 1.67-2.63). This risk was particularly increased in patients with history of AVTE and with a Birmingham Vasculitis Activity Score ≥20 at diagnosis. Patients receiving immunosuppression within 2 months of diagnosis were at lower risk, while antiplatelet or anticoagulant treatment did not confer measurable benefit.Conclusion EGPA is associated with AVTE in approximately one quarter of patients, particularly around diagnosis. Immunosuppressants seemed to exert a protective effect, while anticoagulant and antiplatelet agents did not.Competing Interest StatementDr. Silvia Tamanini worked at ASST Spedali Civili Brescia, Unit of Rheumatology and Immu-nology at the moment of the study. At the moment of publication, she works at Glaxo Smith Kline. All other authors report no conflicts of interest.Clinical TrialThis is a retrospective observational studyFunding StatementThis study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in compliance with the Declaration of Helsinki and approved by the Ethic Committee of the University Hospital Careggi, Florence, Italy (Approval number 12804/CAM_BIO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data are available upon reasonable request, to be sent by email to the corresponding author.